December 13, 2021
Video
The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
NeurologyLive® Brain Games: May 22, 2022
New Research Highlights Reasons, Risk Factors, and Consequences for Self-Discontinuation of Antiseizure Medication in Newly Diagnosed Epilepsy
New Drug Application Submitted for Continuous Subcutaneous Carbidopa/Levodopa Formulation
Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted